Ulrike Fasol1, Annette Frost2, Martin Buechert1, Klaus Mross2, Jann Arends2
1MR Development & Application Center, University Medical Center Freiburg, Freiburg, Germany; 2Tumor Biology Center, Albert-Ludwigs-University Freiburg, Freiburg, Germany
Tumor-growth is critically dependent on blood supply. Thus tumor vasculature presents an ideal target for cancer therapy and numerous antivascular strategies are currently under investigation. DCE(dynamic-contrast-enhanced)-MRI is a non-invasive technique that is capable to measure tumor haemodynamics. It is therefore suitable for monitoring vascular targeted therapies. Contrast enhanced ultrasound (CEUS) is discussed as an alternative in some applications. Whereas DCE-MRI has been used for a couple of years and standards were published, CEUS is a relative new technique and standards have to be developed. In the current pharmacological study 14 patients were examined with both modalities and results were compared.